KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Net Margin (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Net Margin data on record, last reported at 296.76% in Q3 2025.

  • For Q3 2025, Net Margin fell 14315.0% year-over-year to 296.76%; the TTM value through Sep 2025 reached 181.09%, down 159.0%, while the annual FY2024 figure was 120.87%, 18420.0% up from the prior year.
  • Net Margin reached 296.76% in Q3 2025 per NKTR's latest filing, up from 350.85% in the prior quarter.
  • Across five years, Net Margin topped out at 24.85% in Q4 2024 and bottomed at 736.94% in Q2 2022.
  • Average Net Margin over 5 years is 346.44%, with a median of 302.43% recorded in 2022.
  • Peak YoY movement for Net Margin: plummeted -29388bps in 2022, then soared 48755bps in 2023.
  • A 5-year view of Net Margin shows it stood at 587.01% in 2021, then skyrocketed by 48bps to 302.43% in 2022, then surged by 43bps to 171.49% in 2023, then soared by 114bps to 24.85% in 2024, then tumbled by -1294bps to 296.76% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 296.76% in Q3 2025, 350.85% in Q2 2025, and 443.8% in Q1 2025.